Trial Profile
A Multi-center, Randomized, Double-blind, Multi-dose Group, Parallel Group and Placebo Controlled Phase Ib-IIa Clinical Study to Evaluate the Safety and Efficacy of Antiplatelet Thrombolysin for Injection for the Treatment of Patients With Non-ST Segment Elevation Myocardial Infarction (NSTEMI)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Anfibatide (Primary) ; Aspirin; Clopidogrel
- Indications Myocardial infarction; Thrombosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Lee's Pharmaceutical; Zhaoke Pharmaceutical (Hefei)
- 03 Sep 2021 Primary endpoint has been met. (Platelet aggregation), as per Results published in the Pharmacotherapy
- 03 Sep 2021 Results published in the Pharmacotherapy
- 02 Jun 2016 Status changed from active, no longer recruiting to completed.